Pardes Biosciences Net Income

The latest net income for PRDS is $-96M as of June 2023. That compares with $-75M in the prior-year period — down 29.0% year over year. That is below the sector sector average of $110M. Investors often review this figure alongside Pardes Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRDS's net income moved from $-75M to $-96M — a 29.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pardes Biosciences's operating scale or balance-sheet position.

Against its sector companies, PRDS currently prints $-96M for net income, while the sector average sits near $110M. That is roughly 190.5% below the sector mean. Large gaps often invite a closer look at Pardes Biosciences's growth, margins, and balance sheet.

A net income figure of $-96M for PRDS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $110M. Explore the charts below for those layers of context.

After noting PRDS's net income ($-96M), review year-over-year change from $-75M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.